You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 10,137,108

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,137,108

Title:	Nutritional composition useful in the treatment of IBD patients
Abstract:	Compositions and methods are provided that are useful in the treatment of inflammatory bowel disease (IBD) patients. The Compositions and methods are suitable in the prevention or postponement of a relapse in inflammatory bowel disease patients.
Inventor(s):	Blum-Sperisen; Stephanie (Pully, CH), Faure; Magali (Forel, CH), Breuille; Denis (Lausanne, CH), Chuang; Emil (Vevey, CH)
Assignee:	Nestec S.A. (Vevey, CH)
Application Number:	15/544,088
Patent Claims:	1. A method for achieving a result selected from the group consisting of treatment of inflammatory bowel disease (IBD), prolonging remission of IBD, and maintaining or improving the mucosa health status of a patient having IBD or in remission from IBD, the method comprising: administering a composition comprising (a) free form amino acids comprising 9.0-11.0 g threonine in free form/100 g of the composition, 7.0-10.0 g serine in free form/100 g of the composition, and 7.0-9.0 g proline in free form/100 g of the composition; (b) carbohydrates and proteins comprising whey TGF-Beta; and (c) at least one essential fatty acid to the patient, the carbohydrates are 10-50 energy percent of the composition, total proteins comprising the free form amino acids and the proteins comprising the whey TGF-Beta are 30-60 energy percent of the composition, and fats comprising the at least one essential fatty acid are 10-40 energy percent of the composition, the patient has initiated therapy comprising at least one of infliximab or adalimumab at least 12 weeks prior to initiating the administering of the composition to the patient. 2. The method of claim 1, wherein the composition is administered to the patient for at least 10 weeks. 3. The method of claim 1, wherein the administration of the composition is efficacious with respect to medical indications from IBD for a time point selected from any time point between 10 and 60 weeks. 4. The method of claim 1, wherein the IBD is selected from the group consisting of Crohn's Disease and ulcerative colitis. 5. The method of claim 1, wherein the composition is administered in combination with a medicament effective against IBD. 6. The method of claim 1 comprising reconstituting the composition from a dry powder formulation into water. 7. The method of claim 1, wherein the composition comprises 0.1-1.0 g alpha-linolenic acid/100 g, 1.0-8.0 g linolenic acid/100 g, 0.01 g-0.2 g eicosapentaenoic acid/100 g, and 0.005-0.200 g docosahexaenoic acid/100 g. 8. The method of claim 5, wherein the medicament comprises 5-aminosalicylic acid (5-ASA). 9. The method of claim 1, wherein the composition is orally administered to the patient between meals for at least 24 weeks in an amount that contains 400 to 1000 kcal per daily dose. 10. The method of claim 1, wherein the proteins of the composition consist of whey, casein, the threonine in free form, the serine in free form, the proline in free form, and the whey TGF-Beta. 11. The method of claim 1, wherein the threonine in free form, the serine in free form, and the proline in free form are the only free form amino acids in the composition. 12. The method of claim 1, wherein the carbohydrates are 20-40 energy percent of the composition, the total proteins are 35-55 energy percent of the composition, and the fats are 15-35 energy percent of the composition. 13. The method of claim 1, wherein the carbohydrates are 25-35 energy percent of the composition, the total proteins are 40-50 energy percent of the composition, and the fats are 18-25 energy percent of the composition. 14. The method of claim 1, wherein the patient is in remission from IBD.

Details for Patent 10,137,108

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2035-01-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002	⤷ Try a Trial	2035-01-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008	⤷ Try a Trial	2035-01-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013	⤷ Try a Trial	2035-01-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014	⤷ Try a Trial	2035-01-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.